A number of e-commerce platforms in China have already provided treatment pickup services for Eli Lilly's glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide (trade name: Mounjaro).

Indications for tirzepatide include diabetes mellitus, weight loss, and its price currently varies from one merchant to another on Chinese e-commerce platforms.

For example, JD.com's self-operated pharmacy quotes 1,758 yuan for Mounjaro injection in the size of 2.5 mg/0.5 mL*4 doses, an average of about 440 yuan per dose, but it shows unavailability in many regions.

In contrast, several products of the same size sold on Meituan are quoted at around 2,500 yuan, which consumers can buy directly.

Lilly China said on Wednesday that the drug is a self-financed drug, so please refer to the pricing of major pharmaceutical organizations for specific prices.

In addition to tirzepatide, Lilly rival Novo Nordisk's weight-loss drug semaglutide (trade name: Wegovy) has been on the shelves of Chinese e-commerce channels since November.

Meituan shows that 1.5ml (0.68mg/ml) of Wegovy is priced at around 1,350 yuan per unit.